Tags

Type your tag names separated by a space and hit enter

Investigating the risk of maternal-fetal transmission of SARS-CoV-2 in early pregnancy.
Placenta. 2021 03; 106:25-29.P

Abstract

INTRODUCTION

The possibility of vertical transmission of SARS-CoV-2 from the mother to the fetus is one of the most crucial issues regarding the COVID-19 effects on pregnancy. In this study, we aimed to explore the risk of maternal-fetal transmission before 24 weeks of gestation, through analysis of abortion materials collected from PCR-positive women with pregnancy loss. To the best of our knowledge, apart from case reports, this study is the first prospective work on the vertical transmission of SARS-CoV-2 in early pregnancy.

METHODS

The patients who had attended our clinic with the diagnosis of pregnancy loss before 24 weeks of gestation were screened for COVİD-19. Vertical transmission in PCR-positive women was assessed through the presence of SARS-CoV-2 RNA in fetal-placental tissues by rt-PCR test.

RESULTS

24 of 210 (%11,4) pregnant women participating in the study had positive rt-PCR results. Placenta and curettage material samples of these PCR-positive patients were analyzed and all valid test results (21 samples) were negative for SARS CoV-2 RNA. In three cases, the rt-PCR results were invalid due to failed internal controls.

DISCUSSION

In the literature, the possibility of intrauterine vertical transmission of SARS-CoV-2 is still controversial. The findings of the present study did not reveal any evidence of vertical transmission of SARS-CoV-2 in early pregnancy.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Turkish Ministry of Health, Ankara City Hospital, Ankara, Turkey. Electronic address: ozturkfh@gmail.com.Department of Obstetrics and Gynecology, Turkish Ministry of Health, Ankara City Hospital, Ankara, Turkey. Electronic address: eadoga@yahoo.com.Department of Obstetrics and Gynecology, Turkish Ministry of Health, Ankara City Hospital, Ankara, Turkey. Electronic address: dr.selviaydin@hotmail.com.Department of Obstetrics and Gynecology, Turkish Ministry of Health, Ankara City Hospital, Ankara, Turkey. Electronic address: atakantanacan@yahoo.com.Department of Obstetrics and Gynecology, Turkish Ministry of Health, Ankara City Hospital, Ankara, Turkey. Electronic address: sulegoncu@gmail.com.Department of Obstetrics and Gynecology, Turkish Ministry of Health, Ankara City Hospital, Ankara, Turkey. Electronic address: orhanaltinboga@gmail.com.Department of Medical Microbiology, Turkish Ministry of Health, Ankara City Hospital, Ankara, Turkey. Electronic address: bediadinc@gmail.com.Department of Obstetrics and Gynecology, Turkish Ministry of Health, Ankara City Hospital, Ankara, Turkey; University of Health Sciences, Istanbul, Turkey. Electronic address: ozlem.moraloglu@hotmail.com.Department of Obstetrics and Gynecology, Turkish Ministry of Health, Ankara City Hospital, Ankara, Turkey; University of Health Sciences, Istanbul, Turkey. Electronic address: dilekuygur@gmail.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33610934

Citation

Halici-Ozturk, Filiz, et al. "Investigating the Risk of Maternal-fetal Transmission of SARS-CoV-2 in Early Pregnancy." Placenta, vol. 106, 2021, pp. 25-29.
Halici-Ozturk F, Ocal FD, Aydin S, et al. Investigating the risk of maternal-fetal transmission of SARS-CoV-2 in early pregnancy. Placenta. 2021;106:25-29.
Halici-Ozturk, F., Ocal, F. D., Aydin, S., Tanacan, A., Ayhan, S. G., Altinboga, O., Dinc, B., Moraloglu, Ö. T., & Sahin, D. (2021). Investigating the risk of maternal-fetal transmission of SARS-CoV-2 in early pregnancy. Placenta, 106, 25-29. https://doi.org/10.1016/j.placenta.2021.02.006
Halici-Ozturk F, et al. Investigating the Risk of Maternal-fetal Transmission of SARS-CoV-2 in Early Pregnancy. Placenta. 2021;106:25-29. PubMed PMID: 33610934.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Investigating the risk of maternal-fetal transmission of SARS-CoV-2 in early pregnancy. AU - Halici-Ozturk,Filiz, AU - Ocal,Fatma Doga, AU - Aydin,Selvi, AU - Tanacan,Atakan, AU - Ayhan,Sule Göncü, AU - Altinboga,Orhan, AU - Dinc,Bedia, AU - Moraloglu,Özlem Tekin, AU - Sahin,Dilek, Y1 - 2021/02/14/ PY - 2021/01/08/received PY - 2021/01/31/revised PY - 2021/02/09/accepted PY - 2021/2/22/pubmed PY - 2021/4/16/medline PY - 2021/2/21/entrez KW - Early pregnancy KW - Maternal-fetal transmission KW - Placenta KW - SARS-CoV-2 KW - rt-PCR SP - 25 EP - 29 JF - Placenta JO - Placenta VL - 106 N2 - INTRODUCTION: The possibility of vertical transmission of SARS-CoV-2 from the mother to the fetus is one of the most crucial issues regarding the COVID-19 effects on pregnancy. In this study, we aimed to explore the risk of maternal-fetal transmission before 24 weeks of gestation, through analysis of abortion materials collected from PCR-positive women with pregnancy loss. To the best of our knowledge, apart from case reports, this study is the first prospective work on the vertical transmission of SARS-CoV-2 in early pregnancy. METHODS: The patients who had attended our clinic with the diagnosis of pregnancy loss before 24 weeks of gestation were screened for COVİD-19. Vertical transmission in PCR-positive women was assessed through the presence of SARS-CoV-2 RNA in fetal-placental tissues by rt-PCR test. RESULTS: 24 of 210 (%11,4) pregnant women participating in the study had positive rt-PCR results. Placenta and curettage material samples of these PCR-positive patients were analyzed and all valid test results (21 samples) were negative for SARS CoV-2 RNA. In three cases, the rt-PCR results were invalid due to failed internal controls. DISCUSSION: In the literature, the possibility of intrauterine vertical transmission of SARS-CoV-2 is still controversial. The findings of the present study did not reveal any evidence of vertical transmission of SARS-CoV-2 in early pregnancy. SN - 1532-3102 UR - https://www.unboundmedicine.com/medline/citation/33610934/Investigating_the_risk_of_maternal_fetal_transmission_of_SARS_CoV_2_in_early_pregnancy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0143-4004(21)00049-7 DB - PRIME DP - Unbound Medicine ER -